People on the Move Archives - Page 2 of 147 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Innoviva Specialty Therapeutics Reports Lancet Publication of Positive Phase 3 Data for Zoliflodacin in Gonorrhea

December 12, 2025

Delphia Therapeutics Adds Cancer Expert Steve Kelsey, M.D., to Board of Directors

December 9, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

People on the Move

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

Manifold Bio Expands Leadership Team With Appointment of Paula Cobb as Chief Operating Officer

Ankyra Appoints Sailaja Battula, PhD, as Chief Scientific Officer

Suffolk hires Roger Moore to strengthen healthcare construction leadership in California

Most Read

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Innoviva Specialty Therapeutics Reports Lancet Publication of Positive Phase 3 Data for Zoliflodacin in Gonorrhea

Delphia Therapeutics Adds Cancer Expert Steve Kelsey, M.D., to Board of Directors

POPULAR CATEGORY

ABOUT US

FOLLOW US